C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Pipeline Review, H1 2016

  • ID: 3766796
  • Report
  • Region: Global
  • 38 pages
  • Global Markets Direct
1 of 6
C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Pipeline Review, H1 2016

Summary

The report ‘C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Pipeline Review, H1 2016’, provides in depth analysis on C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) targeted pipeline therapeutics.

The report provides comprehensive information on the C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) targeted therapeutics development and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1)
- The report reviews C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) targeted therapeutics and enlists all their major and minor projects
- The report assesses C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6
List of Tables

List of Figures

Introduction

Report Coverage

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) Overview

Therapeutics Development

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Products under Development by Stage of Development

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Products under Development by Therapy Area

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Products under Development by Indication

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Pipeline Products Glance

Late Stage Products

Early Stage Products

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Products under Development by Companies

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Companies Involved in Therapeutics Development

Bristol-Myers Squibb Company

ChemoCentryx, Inc.

Ligand Pharmaceuticals, Inc.

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Drug Profiles

BMS-457 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCX-354 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCX-9588 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Antagonize CCR1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PS-031291 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize CCR1 for Undisclosed Indication - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize CCR and CXCR for Oncology and Autoimmune Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Dormant Projects

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Discontinued Products

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) - Featured News & Press Releases

Apr 18, 2016: ChemoCentryx Announces Immuno-Oncology Data Presentation at the American Association for Cancer Research (AACR) Annual Meeting

Jun 08, 2012: ChemoCentryx Announces Peer-Reviewed Publication Of Positive Phase II Clinical Data With CCX354 In Patients With Rheumatoid Arthritis

Nov 08, 2011: ChemoCentryx Reports Clinical Efficacy For CCX354 In Phase II Study In Patients With Rheumatoid Arthritis

Nov 09, 2010: ChemoCentryx Reports Favorable Phase I Results For CCX354 In Rheumatoid Arthritis At Annual American College Of Rheumatology Meeting

Jun 17, 2010: ChemoCentryx Reports Positive Phase I Study Results For CCX354

Dec 16, 2009: ChemoCentryx Initiates Phase 2 Clinical Trial Of CCX354 For The Treatment Of Rheumatoid Arthritis

May 13, 2008: ChemoCentryx Initiates Clinical Trial Of CCX354 For The Treatment Of Inflammatory Disease

Feb 11, 2008: Pharmacopeia Nominates PS031291 For Development

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Bristol-Myers Squibb Company, H1 2016

Pipeline by ChemoCentryx, Inc., H1 2016

Pipeline by Ligand Pharmaceuticals, Inc., H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6
C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies.The latest report C-C Chemokine Receptor Type 1 - Pipeline Review, H1 2016, outlays comprehensive information on the C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) C-C chemokine receptor type 1 is a protein encoded by the CCR1 gene. CCR1 binds to multiple chemokines (including CCL4, CCL5, CCL6, CCL14, CCL15, CCL16 and CCL23). This receptor is found on peripheral blood lymphocytes and monocytes. This chemokine receptor is restricted to memory T-cells within the lymphocyte pool. This receptor is also designated cluster of differentiation marker CD191. The molecules developed by Companies in Phase II and Preclinical stages are 1 and 6 respectively.

Furthermore, this report also reviews key players involved in C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1-Alpha Receptor or CD191 or CCR1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Bristol-Myers Squibb Company
ChemoCentryx, Inc.
Ligand Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll